Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma.

Delville M, Touzot F, Couzin C, Hmitou I, Djerroudi L, Ouedrani A, Lefrère F, Tuchman-Durand C, Mollet C, Fabreguettes JR, Ferry N, Laganier L, Magnani A, Magrin E, Jolaine V, Saez-Cirion A, Wolstein O, Symonds G, Frange P, Moins-Teisserenc H, Chaix-Baudier ML, Toubert A, Larghero J, Parquet N, Brignier AC, Barré-Sinoussi F, Oksenhendler E, Cavazzana M.

Mol Ther Methods Clin Dev. 2019 Feb 26;13:303-309. doi: 10.1016/j.omtm.2019.02.006. eCollection 2019 Jun 14.

2.

Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Wolstein O, Boyd M, Millington M, Impey H, Boyer J, Howe A, Delebecque F, Cornetta K, Rothe M, Baum C, Nicolson T, Koldej R, Zhang J, Keech N, Camba Colón J, Breton L, Bartlett J, An DS, Chen IS, Burke B, Symonds GP.

Mol Ther Methods Clin Dev. 2014 Feb 12;1:11. doi: 10.1038/mtm.2013.11. eCollection 2014.

3.

Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.

Symonds G, Bartlett JS, Kiem HP, Tsie M, Breton L.

AIDS Patient Care STDS. 2016 Dec;30(12):545-550.

PMID:
27905841
4.

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

Burke BP, Levin BR, Zhang J, Sahakyan A, Boyer J, Carroll MV, Colón JC, Keech N, Rezek V, Bristol G, Eggers E, Cortado R, Boyd MP, Impey H, Shimizu S, Lowe EL, Ringpis GE, Kim SG, Vatakis DN, Breton LR, Bartlett JS, Chen IS, Kitchen SG, An DS, Symonds GP.

Mol Ther Nucleic Acids. 2015 Apr 14;4:e236. doi: 10.1038/mtna.2015.10.

5.

Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.

Ringpis GE, Shimizu S, Arokium H, Camba-Colón J, Carroll MV, Cortado R, Xie Y, Kim PY, Sahakyan A, Lowe EL, Narukawa M, Kandarian FN, Burke BP, Symonds GP, An DS, Chen IS, Kamata M.

PLoS One. 2012;7(12):e53492. doi: 10.1371/journal.pone.0053492. Epub 2012 Dec 31.

6.

Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.

Walker JE, Chen RX, McGee J, Nacey C, Pollard RB, Abedi M, Bauer G, Nolta JA, Anderson JS.

J Virol. 2012 May;86(10):5719-29. doi: 10.1128/JVI.06300-11. Epub 2012 Mar 7.

7.

A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.

Savkovic B, Nichols J, Birkett D, Applegate T, Ledger S, Symonds G, Murray JM.

PLoS Comput Biol. 2014 Jun 19;10(6):e1003681. doi: 10.1371/journal.pcbi.1003681. eCollection 2014 Jun.

8.

Analysis and dissociation of anti-HIV effects of shRNA to CCR5 and the fusion inhibitor C46.

Ledger S, Howe A, Turville S, Aggarwal A, Savkovic B, Ong A, Wolstein O, Boyd M, Millington M, Gorry PR, Murray JM, Symonds G.

J Gene Med. 2018 Feb;20(2-3):e3006. doi: 10.1002/jgm.3006.

PMID:
29552747
9.

Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.

Myburgh R, Ivic S, Pepper MS, Gers-Huber G, Li D, Audigé A, Rochat MA, Jaquet V, Regenass S, Manz MG, Salmon P, Krause KH, Speck RF.

J Virol. 2015 Jul;89(13):6761-72. doi: 10.1128/JVI.00277-15. Epub 2015 Apr 22.

10.

CCR5 as a natural and modulated target for inhibition of HIV.

Burke BP, Boyd MP, Impey H, Breton LR, Bartlett JS, Symonds GP, Hütter G.

Viruses. 2013 Dec 30;6(1):54-68. doi: 10.3390/v6010054.

11.

A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N, Kittipongdaja P, Chen A, Bristol G, Galic Z, Zack JA, Yang O, Chen IS, Lee B, An DS.

Blood. 2010 Feb 25;115(8):1534-44. doi: 10.1182/blood-2009-04-215855. Epub 2009 Dec 17.

12.

Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.

Braun SE, Wong FE, Connole M, Qiu G, Lee L, Gillis J, Lu X, Humeau L, Slepushkin V, Binder GK, Dropulic B, Johnson RP.

Mol Ther. 2005 Dec;12(6):1157-67. Epub 2005 Sep 15.

13.

Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1.

Khamaikawin W, Shimizu S, Kamata M, Cortado R, Jung Y, Lam J, Wen J, Kim P, Xie Y, Kim S, Arokium H, Presson AP, Chen ISY, An DS.

Mol Ther Methods Clin Dev. 2017 Dec 1;9:23-32. doi: 10.1016/j.omtm.2017.11.008. eCollection 2018 Jun 15.

14.
15.
16.

Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.

Ye C, Wang W, Cheng L, Li G, Wen M, Wang Q, Zhang Q, Li D, Zhou P, Su L.

J Virol. 2017 Jan 18;91(3). pii: e01389-16. doi: 10.1128/JVI.01389-16. Print 2017 Feb 1.

20.

Supplemental Content

Support Center